Navigation Links
Misonix Announces New Distribution Agreement for Malaysia and Singapore
Date:3/14/2012

FARMINGDALE, N.Y., March 14, 2012 /PRNewswire/ -- Misonix, Inc. (NasdaqGM: MSON), a medical device company that designs, manufactures and markets innovative therapeutic ultrasonic products worldwide for wound debridement, spine surgery, cosmetic surgery, neurosurgery, laparoscopic surgery and other surgical applications, has entered into a new, three year, exclusive distribution agreement with Humedical Pte. Ltd. for the distribution of the SonaStar® Ultrasonic Surgical Aspirator and the BoneScalpel™ Ultrasonic Bone Cutter.  The agreement provides Humedical with the rights to sell in both Malaysia and the Republic of Singapore.  Included in the agreement are annual minimum purchase requirements.  Government registration and product training are complete and open market sales have commenced.

Humedical is a respected, well-established distributor of state-of-the-art medical devices in both countries, well known for their commitment to service and physician education, with special emphasis in spine surgery, orthopedic surgery and neurosurgery.

The SonaStar is used by neurosurgeons and general surgeons for quick and efficient removal of both hard and soft tumors while sparing most vessels.  OsteoSculpt™ bone sculpting technology can be employed with the SonaStar to safely remove osseous structures, thus providing access to the surgical site.

The BoneScalpel is a tissue specific osteotomy device capable of making precise cuts through bone and hard tissue while largely preserving delicate soft tissue structures.  It offers the convenience and speed of a power instrument without the danger associated with rotary sharps.

"We are quite pleased to have Humedical as a distribution partner for these important markets in Southeast Asia.  Their reputation for successfully introducing advanced medical devices is established and well known to us," said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix.  "We are particularly pleased that they will be selling two of our key products throughout Malaysia and Singapore."

About Misonix
Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually, Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com.

Safe Harbor Statement
With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships. 

Investor Relations Contacts: Misonix Contact: 

Lytham Partners, LLCRichard Zaremba 

Robert Blum, Joe Dorame, Joe Diaz631-694-9555 

602-889-9700invest@misonix.com 

mson@lythampartners.com
'/>"/>

SOURCE Misonix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Misonix Reports a 29% and 24% Increase in Revenue for the Second Quarter and Six Months Fiscal 2012 Financial Results
2. Misonix, Inc. Retains Lytham Partners for Investor Relations
3. Misonix Announces New Distribution Agreement for Thailand
4. Misonix Announces New Distribution Agreement for Algeria
5. Misonix Announces New Distribution Agreement for India
6. Misonix Reports a 14.8% Increase in Revenue for the First Quarter Fiscal 2012 Financial Results
7. Misonix Schedules First Quarter Fiscal 2012 Financial Results Conference Call; November 9, 2011 at 4:30 p.m. Eastern
8. Misonix Announces its Exhibition at the European Association of Neurosurgical Societies
9. Misonix Exhibits at 26th Annual Clinical Symposium on Advances in Skin and Wound Care
10. Misonix Exhibits BoneScalpel™ at the International Meeting on Advanced Spine Techniques
11. Misonix Announces New Distribution Agreement for Austria, Germany & Switzerland
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... Wegener Polyangiitis - Pipeline Review, H2 ... Polyangiitis - Pipeline Review, H2 2015, provides an ... This report provides comprehensive information on the therapeutic ... at various stages, therapeutics assessment by drug target, ... and molecule type, along with latest updates, and ...
(Date:2/4/2016)... -- Summary Breast cancer, a malignant neoplasm, is ... cancer in women worldwide, accounting for 16% of all ... of women diagnosed with breast cancer has increased over ... has declined due to earlier diagnosis and better treatment ... the past four decades, especially with increasing usage of ...
(Date:2/4/2016)... Feb. 4, 2016 Frontier Pharma: Chronic ... First-in-Class Innovation Chronic Obstructive Pulmonary ... chronic inflammation of the airways and lungs. Persistent ... make the disease one of the leading causes ... in the world. COPD is linked to cumulative ...
Breaking Medicine Technology:
(Date:2/6/2016)... ... , ... Shark Finds and Kevin Harrington, along with the Product ... with Belly Bands. , Having a dog is great—except when it wets every couch, ... nothing works, get Belly Bands, the easiest way to stop dogs from wetting ...
(Date:2/5/2016)... ... February 05, 2016 , ... VeloReality ... lighter, sleeker next generation LYNX VR Indoor Trainer with multi-rider capability to an ... and manufacturing not only reduce the weight of the unit, they also enhance ...
(Date:2/5/2016)... ... 2016 , ... The Muscular Dystrophy Association and Sailormen Inc., ... 14th annual “Appetite for a Cure” campaign on Feb. 1 to raise critical ... diseases that severely limit strength and mobility. , Now through March 20, ...
(Date:2/5/2016)... ... February 05, 2016 , ... After years as an ... Burn Unit, plastic and cosmetic surgeon Dr. Wayne Carman transitioned to chief of the ... successfully completed his first three-year term as chief and began a second three-year term ...
(Date:2/5/2016)... ... February 05, 2016 , ... The American public tends ... water may be safer than regular municipal or well water. The recent experience with ... Sharon Kleyne, could go a long way toward increasing public acceptance of recycled waste ...
Breaking Medicine News(10 mins):